Article Details

Global Scenario of Canine Parvovirus Mutants: Epidemiology, Diagnostics and Immunoprophylactic Agents

[ ISSN : 2689-1565 ]

Abstract

S.Nandi, GK Sharma, Vikas Gupta, Pallavi Deol, Vishal Chander, UK De* and VK Gupta

Division of Veterinary Medicine, Centre for Animal Disease Research and Diagnosis, Indian Veterinary Research Institute, Izatnagar, India

Corresponding Author:

UK De, Division of Veterinary Medicine, Centre for Animal Disease Research and Diagnosis, Indian Veterinary Research Institute, Izatnagar, India,

Keywords: Canine parvovirus-2 (CPV-2); CPV-2a; CPV-2b; CPV-2c; New CPV-2a; New CPV-2b; Asp300 (2a/2b); Hemorrhagic enteritis; Myocarditis; Canine; Vaccination; Feline panleukopenia virus (FPV); Raccoon parvovirus (RPV); Mine enteritis virus (MEV); Blue fox parvovirus (BFPV)

Abstract

Canine parvovirus 2 (CPV-2) is one of the most important enteropathogen of dogs emerged in 1978 and manifested by two forms namely gastroenteritis and myocarditis. It is characterized by depression, loss of appetite, vomiting and leukopenia. CPV-2 is probably evolved from a very closely related virus in cats, feline panleukopenia virus (FPLV) or a closely related carnivore parvovirus. It caused high morbidity of 100% and low mortality of 10% in adult dogs and 91% in pups. Over the years a number of variants namely CPV-2a, CPV-2b, CPV-2c, New CPV-2a, New CPV-2b and Asp300 (2a/2b) have been reported from different countries in the world with varying degree of pathogenic potential. Although CPV-2 differ from FPV by 6 amino acids in the VP2 protein, subsequent variants differ from CPV-2 only in one or two places. Further, CPV-2 affects only dogs, new variants expanded their host range to cat as well. There are a number of different serological and molecular tests (PCR, nested PCR, SYBR Green based real time PCR, Taqman based real time PCR, Minor grove binding assay based PCR) available for prompt, specific and accurate diagnosis of the disease. Some molecular tests not only detect the CPV-2 but also identify the variant of CPV-2 involved in disease outbreak. Further, both live attenuated and inactivated vaccines are available to control the disease in animals. Besides, new generation vaccines namely recombinant vaccine, peptide vaccine and DNA vaccine have been developed for control of the disease in canines effectively and efficiently. However, new generation vaccines have not been issued license to be used in the field condition. Again, the presence of maternal antibodies often interferes with the active immunization with live attenuated vaccine and there always exists a window of susceptibility in spite of following proper immunization regimen. Lastly, judicious use of the vaccines in pet dogs, stray dogs and wild canids keeping in mind the new variants of the CPV-2 along with the proper sanitation and disinfection practices must be implemented for the successful control the disease.

Citation

Nandi S, Sharma GK, Gupta V, Deol P, Chander V, et al. (2019) Global Scenario of Canine Parvovirus Mutants: Epidemiology, Diagnostics and Immunoprophylactic Agents. JSM Vet Med Res 2: 12.

Download PDF

Received: July 05, 2019

Accepted: August 25, 2019

Published: August 27, 2019